Valuation: Recordati

Market Cap 10.45B 11.89B 9.71B 8.91B 16.75B 1,145B 17.01B 115B 45.07B 563B 44.65B 43.69B 1,947B P/E 2026 *
20.7x
P/E 2027 * 17.1x
Enterprise Value 12.2B 13.89B 11.35B 10.41B 19.56B 1,338B 19.86B 135B 52.64B 658B 52.15B 51.02B 2,274B EV / Sales 2026 *
4.39x
EV / Sales 2027 * 3.95x
Free-Float
50.48%
Yield 2026 *
2.99%
Yield 2027 * 3.31%
1 day-3.33%
3 months+1.84%
6 months-11.37%
Current year-11.37%
Current year 55.88
Extreme 55.88
60
1 year 55.88
Extreme 55.88
60
3 years 46
Extreme 46
65.44
5 years 36
Extreme 36
65.44
10 years 31.7
Extreme 31.7
65.44
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2021
Director of Finance/CFO 56 01/01/2026
Chief Tech/Sci/R&D Officer 56 01/10/2023
Director TitleAgeSince
Chairman 54 01/12/2021
Chairman 57 12/06/2018
Director/Board Member 53 12/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%-.--% - - 11.89B
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.11%+1.33%+26.20%+52.36% 404.78B
Weighted average by Cap. +0.75%+1.95%+35.99%+78.15%

Financials

2026 *2027 *
Net sales 2.78B 3.17B 2.59B 2.37B 4.46B 305B 4.53B 30.7B 11.99B 150B 11.88B 11.63B 518B 3B 3.42B 2.79B 2.56B 4.82B 329B 4.89B 33.16B 12.96B 162B 12.84B 12.56B 560B
Net income 565M 643M 525M 482M 905M 61.9B 919M 6.23B 2.44B 30.43B 2.41B 2.36B 105B 673M 766M 626M 574M 1.08B 73.79B 1.1B 7.43B 2.9B 36.28B 2.88B 2.81B 125B
Net Debt 1.75B 2B 1.63B 1.5B 2.81B 192B 2.86B 19.37B 7.57B 94.57B 7.5B 7.34B 327B 1.43B 1.63B 1.33B 1.22B 2.29B 157B 2.33B 15.8B 6.17B 77.12B 6.12B 5.98B 267B
Logo Recordati
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (58.7%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (41.3%). Net sales are distributed geographically as follows: Italy (12.6%), Europe (53.7%), America (23.1%), Asia and Oceania (7.8%) and Africa (2.8%).
Employees
4,654
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
51.35EUR
Average target price
58.89EUR
Spread / Average Target
+14.68%

Quarterly revenue - Rate of surprise